When the U.S. Food and Drug Administration made the opioid overdose reversal drug naloxone an over-the-counter medication last summer, health care advocates praised the removal of the prescription barrier as an effective tool to prevent fentanyl deaths.

Read more

(March 6, 2024) The Reagan-Udall Foundation for the FDA has announced new officers and two new members of its Board of Directors. 

Adrian F. Hernandez, MD, MHS, a Board member since 2019, has been elected to serve as the Board’s Vice Chair. Debra L. Ness, MS, on the Board since 2022, assumes the role of Treasurer. Lynne Zydowsky, PhD, a Board member since 2019, is the board’s new Secretary.